|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2005-3-25
|
|
pubmed:abstractText |
Epoprostenol (prostaglandin I(2)) has become recognized as a therapeutic breakthrough that can improve hemodynamics and survival in patients with primary pulmonary hypertension (PPH). However, a significant number of patients have PPH that is refractory to epoprostenol, and lung transplantation has been the only remaining treatment option.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1346-9843
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
69
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
461-5
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15791043-Administration, Oral,
pubmed-meshheading:15791043-Adult,
pubmed-meshheading:15791043-Drug Resistance,
pubmed-meshheading:15791043-Drug Synergism,
pubmed-meshheading:15791043-Drug Therapy, Combination,
pubmed-meshheading:15791043-Epoprostenol,
pubmed-meshheading:15791043-Female,
pubmed-meshheading:15791043-Humans,
pubmed-meshheading:15791043-Hypertension, Pulmonary,
pubmed-meshheading:15791043-Male,
pubmed-meshheading:15791043-Middle Aged,
pubmed-meshheading:15791043-Piperazines,
pubmed-meshheading:15791043-Purines,
pubmed-meshheading:15791043-Salvage Therapy,
pubmed-meshheading:15791043-Sulfones,
pubmed-meshheading:15791043-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol.
|
|
pubmed:affiliation |
Cardiopulmonary Division, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
